The HFSA Heart Failure Seminar: Focus on HFSA Scientific Statement on Cardio-Oncology and Heart Failure – A Focus on Key Takeaways. This dynamic, case-based virtual seminar will explore the Cardio-Oncology and Heart Failure Scientific Statement from the Heart Failure Society of America. Hear directly from the statement's authors as they discuss four complex case presentations, followed by insightful panel discussions.
Following this activity, participants will be better able to:
Welcome Remarks and Event BackgroundMichelle Bloom, MD and Ana Barac, MD, PhD
Case Presentation and Panel Discussion
Daniel Lenihan, MD & Panelists
Case Presentation #1 and Panel Discussion
A Case of Lung Malignancy and EGFR Tyrosine Kinase Inhibitor Induced Cardiomyopathy
Patient with Lung Cancer and Osimertinib who develops cardiomyopathy; discuss how can present, when/if to hold Osi, experience with LV recovery and rechallenge, follow up surveillance.
Case Presentation #2 and Panel Discussion
TBD & Panelists
A Case of Metastatic Breast Cancer Complicated by the Development of Cardiomyopathy and Acute Heart Failure
Patient with HER2+ metastatic breast cancer and at least mild heart failure, highlighting early diagnosis and management, GDMT, how to handle holding / med optimization, and rechallenging therapy; discuss how while permissive tox describes an approach in asymptomatic pts, we sometimes extrapolate to sicker / higher risk in absence of data when weighed against cancer risk.
Case Presentation #3 and Panel Discussion
A Case of Chronic Myelogenous Leukemia and Use of Bruton Tyrosine Kinase Inhibitor-Associated Cardiac Complications
Patient with CLL on BTK, diagnosis and presentation of hypertension and HFpEF , incorporate AF in case, how to diagnose, monitor, and treat; discuss how these agents can lead to HFpEF in setting of AF/HTN; ideally also discuss handling of drug-drug interactions with respect to AC and antiarrythmics, handling of antiplatelets.
Case Presentation #4 and Panel Discussion
Nicolas Palaskas, MD & Panelists
A Case of Fulminant Immune Checkpoint Inhibitor-Related Myocarditis
Patient with ICI Myocarditis (fulminant) and how to make decisions on when/if to use second and third immunomodulatory agent +/- when role for MCS/ECMO (and whether ultimately that patient would be appropriate to move on to LVAD), Diagnostic criteria, role of EMB, treatment (when to add abatacept and/or other agents), relationship to cardiogenic shock.
Case Presentation #5 and Panel Discussion
Anju Nohria, MD, MSc & Panelists
A Case of Recent Malignancy and Orthotopic Heart Transplant Consideration
Patient with history of DCIS how we would evaluate that patient for OHT candidacy (and perhaps how post OHT surveillance might be different than typical pt), how to determine risk of post OHT malignancy and whether this should influence post OHT surveillance.
Closing RemarksMichelle Bloom and Ana Barac
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for PHarmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.The Heart Failure Society of America designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.50 contact hours.
The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.50 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-25-003-L01-P (on-site/live attendance only); JA4008267-0000-25-004-H01-P (on-demand/home study)
The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.